Uniqure ($QURE) and Spark Therapeutics ($ONCE) are squaring off over who will soon provide the best haemophilia B gene therapy. Meanwhile, the companies have acknowledged that intellectual property issues may be critical to which drug will come out on top. Will the patent issues cloud either drug’s commercial performance?
Read More
Patent Valuation, Monetization and Investments
Patent Valuation, Monetization and Investments